Coordination of Immune-Stroma Crosstalk by IL-6 Family Cytokines

Stromal cells are a subject of rapidly growing immunological interest based on their ability to influence virtually all aspects of innate and adaptive immunity. Present in every bodily tissue, stromal cells complement the functions of classical immune cells by sensing pathogens and tissue damage, co...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 10; p. 1093
Main Author West, Nathaniel R.
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 15.05.2019
Subjects
cytokines
fibrosis
immune
Immunology
inflammation
stromal cells
cytokines
fibrosis
immune
inflammation
stromal cells
Online AccessGet full text

Cover

More Information
Summary:Stromal cells are a subject of rapidly growing immunological interest based on their ability to influence virtually all aspects of innate and adaptive immunity. Present in every bodily tissue, stromal cells complement the functions of classical immune cells by sensing pathogens and tissue damage, coordinating leukocyte recruitment and function, and promoting immune response resolution and tissue repair. These diverse roles come with a price: like classical immune cells, inappropriate stromal cell behavior can lead to various forms of pathology, including inflammatory disease, tissue fibrosis, and cancer. An important immunological function of stromal cells is to act as information relays, responding to leukocyte-derived signals and instructing leukocyte behavior in kind. In this regard, several members of the interleukin-6 (IL-6) cytokine family, including IL-6, IL-11, oncostatin M (OSM), and leukemia inhibitory factor (LIF), have gained recognition as factors that mediate crosstalk between stromal and immune cells, with diverse roles in numerous inflammatory and homeostatic processes. This review summarizes our current understanding of how IL-6 family cytokines control stromal-immune crosstalk in health and disease, and how these interactions can be leveraged for clinical benefit.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Carl D. Richards, McMaster University, Canada; Nathan Karin, Technion Israel Institute of Technology, Israel
This article was submitted to Immunological Tolerance and Regulation, a section of the journal Frontiers in Immunology
Edited by: Teruki Dainichi, Kyoto University, Japan
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2019.01093